🚨 Alpha Signal: Olympus Corporation (7733.T) 📉 Price Drop 12.4%
🚨 Alpha Bond Signal Alert
Bond Market Analysis
Olympus Corporation (7733.T) -12.4% at 2026-02-16 12:00 JST from 2026-02-13 15:30 JST
| 🕒 Time (Local) | 🌐 English Summary | 📰 Original Headline (linked) |
|---|---|---|
| 2026-02-16 10:24 JST | Minkabu reports Olympus shares are sharply lower and down for a third straight day, with the stock around –12.7% intraday, after the company cut FY March 2026 consolidated operating profit guidance from ¥136.0bn to ¥75–87bn (–46.4% to –53.8% YoY), citing progress to date and shipment halts in the Surgical Intervention business; sales and dividend forecasts were left unchanged. (minkabu.jp) | オリンパスは大幅安、今期利益予想を下方修正 |
| 2026-02-16 09:29 JST | A Kabutan/Livedoor piece ranks “negative earnings impact” names and lists Olympus in the top decliners, noting that FY March 2026 Q3 cumulative net profit fell 43.2% YoY to ¥43.3bn, with the stock down about 15% from pre‑results levels, indicating investors are selling on the sharp profit deterioration. (news.livedoor.com) | 決算マイナス・インパクト銘柄 〔東証プライム〕寄付 … 三井海洋、オリンパス、住友林 (2月13日発表分) |
| 2026-02-16 09:13 JST | Bloomberg (via Yahoo! Japan) reports Olympus shares plunge as much as 11% to ¥1,650, the biggest intraday fall since June 2025, after the firm cut FY March 2026 operating profit guidance to ¥75–87bn from ¥136bn; the article highlights that the revision reflects the impact of U.S. FDA import halts on several endoscope and surgical products, which are weighing on earnings, and cites an SMBC Nikko analyst calling the guidance change “negative.” (finance.yahoo.co.jp) | オリンパス株が大幅安、営業利益を下方修正－FDA差し止めなど影響 |
| 2026-02-14 03:38 JST | Investing.com Japan summarizes Olympus’s FY 2026 Q3 results and notes that, alongside the earnings, management cut revenue guidance by 2% on a constant‑currency basis and updated outlook figures to reflect ongoing “ship‑holds” in the SIS division; it reports the stock fell 5.22% to ¥1,954.5 on Feb. 13 as investors reacted to continued operational disruptions and weaker margins. (jp.investing.com) | オリンパス、2026年度第3四半期：出荷停止の課題により収益見通しを2%下方修正 |
| 2026-02-13 15:30 JST | Kabutan/Minkabu’s post‑close article on the Q3 results reports that FY March 2026 Q3 cumulative net profit dropped 43.2% YoY to ¥43.3bn, and that the company simultaneously cut full‑year net profit guidance from ¥94bn to a range of ¥50–59bn; Q3 quarterly net profit fell 48.3% YoY and the operating margin slid from 15.2% to 9.2%, reinforcing a bearish earnings picture. (minkabu.jp) | オリンパス、今期最終を500億～590億円に下方修正 |
| 2026-02-13 15:30 JST | Official TDnet/IR filing “Notice Regarding Revision of Full‑Year Consolidated Earnings Forecast” details a major downgrade to FY March 2026 guidance: while sales remain at ¥998.0bn, operating profit is cut from ¥136.0bn to ¥75–87bn, pre‑tax profit from ¥131.0bn to ¥71–83bn, and net profit from ¥94.0bn to ¥50–59bn (roughly –37% to –47% vs. prior forecast), with Olympus citing Q3 progress and the impact of shipment stoppages in the Surgical Intervention business. (olympus.co.jp) | 通期連結業績予想の修正に関するお知らせ |
| 2026-02-13 15:30 JST | The official FY March 2026 Q3 earnings release (決算短信) shows revenue down 1.4% YoY to ¥715.4bn and operating profit down 35.4% to ¥70.3bn, with pre‑tax profit down 36.4% and net profit attributable to owners down 43.2%; Olympus attributes the profit slump to higher cost of sales from U.S. tariff impacts and unfavorable mix, recall‑related costs in SIS, increased SG&A and restructuring charges including global headcount optimization, underscoring deteriorating profitability. (olympus.co.jp) | 2026年３月期 第３四半期決算短信〔ＩＦＲＳ〕（連結） |
Don't miss what's next. Subscribe to Morning Espresso: